| Assessment Status | Rapid Review Complete |
| HTA ID | 24001 |
| Drug | Liraglutide |
| Brand | Saxenda® |
| Indication | Liraglutide is indicated as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: • obesity (body mass index (BMI) corresponding to ≥30 kg/m2 for adults by international cut-off points) and • body weight above 60 kg* |
| Assessment Process | |
| Rapid review commissioned | 05/01/2024 |
| Rapid review completed | 09/02/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that liraglutide not be considered for reimbursement at the submitted price*. |
*The Applicant is requesting reimbursement in a subgroup of the licensed population, namely:
Adolescent patients between the ages 12 to 16 years with a BMI greater than the 99.5th percentile and two or more of the following co-morbidities:
- Uncontrolled metabolic complications.
- Biomechanical complications requiring treatment or limited mobility.
- Shortness of breath.
- Significant psychosocial complications or concerns.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
